GSK has announced on 16 June an agreement with Dr. Reddy’s to develop and market selected products across an extensive number of emerging markets, excluding India.
Under the terms of the agreement, the products will be manufactured by Dr. Reddy’s, and licensed and supplied by GSK in various countries in Africa, the Middle East, Asia Pacific and Latin America.
Abbas Hussain, President Emerging Markets, GSK said: "This new alliance will combine Dr. Reddy's portfolio of quality branded pharmaceuticls together with GSK's extensive sales and marketing capabilities. Together we will be able to deliver more medicines of value to more patients in these countries."
Dr. Reddy’s is an emerging global pharmaceutical company established in 1984 and its three core businesses are Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
